Browsing by Author "Bircan A."

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Epidemiology and distribution of interstitial lung diseases in Turkey
    (2014) Musellim B.; Okumus G.; Uzaslan E.; Akgün M.; Cetinkaya E.; Turan O.; Akkoclu A.; Hazar A.; Kokturk N.; Calisir H.C.; Sever F.; Kiter G.; Celik G.; Bilgin S.; Kurutepe M.; Uzun O.; Tabak L.; Ozdemir O.; Turker H.; Ogus C.; Kiral N.; Ozkan M.; Yalniz E.; Camsari G.; Dogan T.; Yilmaz U.; Cildag O.; Yildiz F.; Hanta I.; Oztuna F.; Arik D.; Goktalay T.; Kanmaz D.; Yilmaz V.; Altiay G.; Komurcuoglu B.; Ozkan G.; Erbaycu A.; Dogrul M.I.; Ongen G.; Tuncay E.; Dabak G.; Sakar A.; Bircan A.; Uzel I.; Kalpaklioglu F.; Gülbay B; Bulbul Y.; Gulbanu H.; Havlucu Y.; Ekici Z.; Zamani A.; Caglayan B.; Kayacan O.; Dursunoglu N.
    Introduction: There is very few data on the epidemiological features of interstitial lung diseases (ILD) in the literature. These studies on this subject suffer from limited number of patients. Objective: The goal of this study was to evaluate the epidemiological features of ILD in Turkey. Methods: Fifty-four investigators, 31 centres in 19 cities from six regions of Turkey, participated in the study. Two thousand two hundred forty-five newly diagnosed patients (51.8% females), led by Turkish Thoracic Society Clinical Problems Study Group, enrolled in this prospective study. Results: The mean age was 51.8±16.7 years. The mean age among males was 50.5±18.6 years and 53.0±14.6 years among females (P<0.001). 23.8% of the cases had ILD with known causes, while 39.4% were in granulomatous group, 23.7% were idiopathic, and 4.4% were in the unclassified group. Overall, histopathologically confirmed diagnosis rate was 40.4%. Sarcoidosis was the most common disease (37%), whereas cases with idiopathic pulmonary fibrosis (IPF) constituted 19,9% of patients. 53% of the sarcoidosis patients were females, and the ratio reaches to 75% under 50 years of age (for this group, IPF ratio is %3). In contrast, sarcoidosis and IPF ratios were equal in males (25%). Sarcoidosis was 8% in men over 50, while IPF was %45. Conclusion: The overall incidence of ILD in Turkey was computed to be 25.8/100000. © 2013 John Wiley & Sons Ltd.
  • No Thumbnail Available
    Item
    Patient and physician delay in the diagnosis and treatment of non-small cell lung cancer in Turkey
    (Elsevier Ltd, 2015) Yurdakul A.S.; Kocatürk C.; Bayiz H.; Gürsoy S.; Bircan A.; Özcan A.; Akkoçlu A.; Uluorman F.; Çelik P.; Köksal D.; Ulubaş B.; Sercan E.; Özbudak T.; Göksel T.; Önalan T.; Yamansavci E.; Türk F.; Yuncu G.; Çopuraslan T.; Mardal T.; Tuncay E.; Karamustafaoğlu A.; Yildiz P.; Seçik F.; Kaplan M.; Çağlar E.; Ortaköylü M.; Önal M.; Turna A.; Hekimoğlu E.; Dalar L.; Altin S.; Gülhan M.; Akpinar E.; Savas T.; Firat N.; Çamsari G.; Özkan G.; Çetinkaya E.; Kamiloğlu E.; Çelik B.; havlucu Y.
    Aim: The early diagnosis and treatment of lung cancer are important for the prognosis of patients with lung cancer. This study was undertaken to investigate patient and doctor delays in the diagnosis and treatment of NSCLC and the factors affecting these delays. Materials and methods: A total of 1016 patients, including 926 (91.1%) males and 90 (8.9%) females with a mean age of 61.5. ±. 10.1 years, were enrolled prospectively in this study between May 2010 and May 2011 from 17 sites in various Turkish provinces. Results: The patient delay was found to be 49.9. ±. 96.9 days, doctor delay was found to be 87.7. ±. 99.6 days, and total delay was found to be 131.3. ±. 135.2 days. The referral delay was found to be 61.6. ±. 127.2 days, diagnostic delay was found to be 20.4. ±. 44.5 days, and treatment delay was found to be 24.4. ±. 54.9 days. When the major factors responsible for these delays were examined, patient delay was found to be more frequent in workers, while referral delay was found to be more frequent in patients living in villages (. p<. 0.05). We determined that referral delay, doctor delay, and total delay increased as the number of doctors who were consulted by patients increased (. p<. 0.05). Additionally, we determined that diagnostic and treatment delays were more frequent at the early tumour stages in NSCLC patients (. p<. 0.05). Discussion: The extended length of patient delay underscores the necessity of educating people about lung cancer. To decrease doctor delay, education is a crucial first step. Additionally, to further reduce the diagnostic and treatment delays of chest specialists, multidisciplinary management and algorithms must be used regularly. © 2015 Elsevier Ltd.
  • No Thumbnail Available
    Item
    A New Inflammatory Prognostic Index, Based on C-reactive Protein, the Neutrophil to Lymphocyte Ratio and Serum Albumin is Useful for Predicting Prognosis in Non-Small Cell Lung Cancer Cases
    (Asian Pacific Organization for Cancer Prevention, 2016) Dirican N.; Dirican A.; Anar C.; Atalay S.; Ozturk O.; Bircan A.; Akkaya A.; Cakir M.
    Purpose: We aimed to establish an inflammatory prognostic index (IPI) in early and advanced non-small cell lung cancer (NSCLC) patients based on hematologic and biochemical parameters and to analyze its predictive value for NSCLC survival. Materials and Methods: A retrospective review of 685 patients with early and advanced NSCLC diagnosed between 2009 and 2014 was conducted with collection of clinical, and laboratory data. The IPI was calculated as C-reactive protein × NLR (neutrophil/ lymphocyte ratio)/serum albumin. Univariate and multivariate analyses were performed to assess the prognostic value of relevant factors. Results: The optimal cut-off value of IPI for overall survival (OS) stratification was determined to be 15. Totals of 334 (48.8%) and 351 (51.2%) patients were assigned to high and low IPI groups, respectively. Compared with low IPI, high IPI was associated with older age, greater tumor size, high lymph node involvement, distant metastases, advanced stage and poor performance status. Median OS was worse in the high IPI group (low vs high, 8.0 vs 34.0 months; HR, 3.5; p<0.001). Progression free survival values of the patients who had high vs low IPI were determined 6 months (95% CI:5.3-6.6) and 14 months (95% CI:12.1-15.8), respectively (HR; 2.4, P<0.001). On multivariate analysis, stage, performance status, lactate dehydrogenase and IPI were independent prognostic factors for OS. Subgroup analysis showed IPI was generally a significant prognostic factor in all clinical variables. Conclusion: The described IPI may be an inexpensive, easily accessible and independent prognostic index for NSCLC patients, useful for clinical practice. © 2016, Asian Pacific Journal of Cancer Prevention. All Rights Reserved.
  • No Thumbnail Available
    Item
    A new inflammatory prognostic index, based on C-reactive protein, the neutrophil to lymphocyte ratio and serum albumin is useful for predicting prognosis in non-small cell lung cancer cases
    (Asian Pacific Organization for Cancer Prevention, 2016) Dirican N.; Dirican A.; Anar C.; Atalay S.; Ozturk O.; Bircan A.; Akkaya A.; Cakir M.
    Purpose: We aimed to establish an inflammatory prognostic index (IPI) in early and advanced non-small cell lung cancer (NSCLC) patients based on hematologic and biochemical parameters and to analyze its predictive value for NSCLC survival. Materials and Methods: A retrospective review of 685 patients with early and advanced NSCLC diagnosed between 2009 and 2014 was conducted with collection of clinical, and laboratory data. The IPI was calculated as C-reactive protein × NLR (neutrophil/ lymphocyte ratio)/serum albumin. Univariate and multivariate analyses were performed to assess the prognostic value of relevant factors. Results: The optimal cut-off value of IPI for overall survival (OS) stratification was determined to be 15. Totals of 334 (48.8%) and 351 (51.2%) patients were assigned to high and low IPI groups, respectively. Compared with low IPI, high IPI was associated with older age, greater tumor size, high lymph node involvement, distant metastases, advanced stage and poor performance status. Median OS was worse in the high IPI group (low vs high, 8.0 vs 34.0 months; HR, 3.5; p < 0.001). Progression free survival values of the patients who had high vs low IPI were determined 6 months (95% CI:5.3-6.6) and 14 months (95% CI:12.1-15.8), respectively (HR; 2.4, P < 0.001). On multivariate analysis, stage, performance status, lactate dehydrogenase and IPI were independent prognostic factors for OS. Subgroup analysis showed IPI was generally a significant prognostic factor in all clinical variables. Conclusion: The described IPI may be an inexpensive, easily accessible and independent prognostic index for NSCLC patients, useful for clinical practice.